Instrument Inactif

Communiqués InterCure Ltd. TEL AVIV STOCK EXCHANGE

Actions

INCR

IL0011063760

Installations et services en soins de santé

Communiqués

01/05	InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow	AQ
03/03	InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement	AQ
19/02	InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million	AQ
03/11	InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation	AQ
08/10/25	InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow	AQ
19/09/25	InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands	AQ
01/05/25	InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025	PR
13/02/25	InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak	PR
03/02/25	InterCure : Immediate Report	PU
02/02/25	InterCure : A meeting to be held on February 3, 2025-Amendment regarding the private placement	PU
27/01/25	InterCure : Immediate Report	PU
20/12/24	InterCure : NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JANUARY 27, 2025 Form 6 K	PU
20/12/24	InterCure : has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility Form 6 K	PU
20/12/24	InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility	PR
26/11/24	InterCure : Immediate Report of Meeting	PU
25/11/24	InterCure : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 30, 2024 Form 6 K	PU
04/11/24	InterCure : Immediate Report	PU
28/10/24	InterCure : Immediate Report	PU
30/08/24	InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million	AQ
28/08/24	InterCure Announces Expansion of its Strategic partnership with Cookies to Germany	BU
22/05/24	InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference	BU
21/05/24	InterCure : Immediate Report	PU
01/05/24	InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million	BU
01/05/24	InterCure : FORM 20-F For the fiscal year ended December 31, 2023	PU
01/05/24	InterCure : Announces FY2023 Result	PU